Adverse reactions and treatment methods of Datopotamab

Datopotamab (Datopotamab) is an antibody drug conjugate (ADC). Its mechanism is to combine cytotoxic drugs with antibodies and accurately deliver them to tumor cells. It has strong anti-cancer activity. However, like other anticancer drugs, dabrotuzumab has its adverse effects and patients require careful monitoring and appropriate management while receiving treatment.

First, one of the common adverse reactions of dabrotumumab is bone marrow suppression. Patients may experience problems such as leukopenia, thrombocytopenia, or anemia. These adverse reactions are often caused by the cytotoxic components of the drug. Reduced leukocytes can make patients susceptible to infection, so during treatment, doctors usually monitor blood routine regularly and intervene accordingly if abnormalities are found, such as using growth factor stimulators or temporarily discontinuing medication.

Secondly, gastrointestinal reactions are also common side effects of dabrotuzumab treatment. Patients may experience nausea, vomiting, diarrhea and other symptoms. To relieve these symptoms, appropriate symptomatic treatments, such as anti-nausea medications or antidiarrheal medications, are usually given during treatment. For patients with more severe symptoms, medication dosage may need to be adjusted or temporarily discontinued to ensure patient comfort and safety.

Skin reactions are also one of the common problems with dabrotuzumab treatment, especially rash. The rash may manifest as skin erythema, itching, papules and other symptoms. In most cases, skin reactions are mild and resolve on their own, but if the rash persists or worsens, topical medications or other treatments may be needed for relief. Severe skin reactions require discontinuation of dabrotuzumab and further evaluation.

Additionally, dabrotuzumab may cause liver damage. Symptoms of liver insufficiency may include jaundice, elevated ALT and AST. Patients need to regularly monitor liver function indicators during treatment. Once abnormalities are found, the drug dosage needs to be adjusted or other treatment measures need to be taken.

Keyword tags:

Dedabrotuzumab, adverse reactions, cytotoxicity, myelosuppression, leukopenia, gastrointestinal reactions, skin reactions, liver damage, drug modification, immune reactions

Reference materials:https://go.drugbank.com/drugs/DB16410